Scancell Holdings Plc Scancell Appoints Sath Nirmalananthan as CFO (5469K)
29 August 2023 - 4:00PM
UK Regulatory
TIDMSCLP
RNS Number : 5469K
Scancell Holdings Plc
29 August 2023
29 August 2023
Scancell Holdings plc
("Scancell" or the "Company")
Scancell Appoints Sath Nirmalananthan as Chief Financial
Officer
Keith Green to retire as Director of Finance but to remain as
Company Secretary
Scancell Holdings plc (AIM: SCLP), the developer of novel
immunotherapies for the treatment of cancer and infectious disease,
today announces the appointment of Sath Nirmalananthan as Chief
Financial Officer (CFO), with immediate effect.
Sath Nirmalananthan is an experienced finance professional with
over 15 years experience across healthcare in FTSE and NASDAQ
listed companies, investment banking and audit. Before joining
Scancell, Sath was Chief Financial Officer for Europe, Middle-East
and Africa at Prenetics, a leading genomics-driven health sciences
company. Prior to that, Sath worked at Reckitt where he was Finance
Director for Group Reporting and subsequently for eCommerce in
Reckitt's Health Division. Sath has also held senior positions at
BTG plc, a specialty pharmaceutical company, including Director of
Group Reporting and Director of FP&A of interventional
oncology. Earlier in his career, he was an equity research analyst
in the healthcare team at Nomura and prior to that an auditor at
KPMG. Sath earned a BSc in Pharmacology from King's College,
London, UK and holds an ACA (ICAEW), Chartered Accountant
qualification. Sath is also a Non-Executive member of the audit
committee at The Institute of Cancer Research (ICR).
Prof Lindy Durrant, Chief Executive Officer of Scancell ,
commented : " We are excited to have Sath join us as Chief
Financial Officer. His financial acumen and extensive track record
of building value in emerging biopharmaceutical companies will
benefit Scancell in our next stage of evolution. I look forward to
working with him closely as we continue to focus the clinical
development of our two lead cancer vaccine assets, SCIB1 and Modi-1
, whilst continuing to leverage the potential of our proprietary
antibody platform through additional licensing and revenue
generating opportunities. We are very grateful for Keith ' s
excellent financial guidance which has been invaluable to Scancell
' s success to date and are pleased that he will continue as
Company Secretary."
Commenting on his appointment as Chief Financial Officer, Sath
Nirmalananthan said: " I am excited to be joining Scancell at such
a pivotal time. With the Phase 2 single arm SCOPE trial progressing
and initial topline data readouts expected this year and Modi-1
next year, the Company is positioned with highly valuable science
and near-term inflection points that should deliver value to our
shareholders. I look forward to working with Lindy and the wider
team and am excited by the potential of what can be achieved."
For further information, please contact:
Scancell Holdings plc +44 (0) 20 3709 5700
Professor Lindy Durrant, CEO
Dr Jean-Michel Cosséry, Non-Executive Chairman
Stifel Nicolaus Europe Limited (Nominated Adviser
and Joint Broker) +44 (0) 20 7710 7600
Nicholas Moore/Samira Essebiyea/William Palmer-Brown
(Healthcare Investment Banking)
Nick Adams/Nick Harland (Corporate Broking)
Panmure Gordon (UK) Limited (Joint Broker) +44 (0) 20 7886 2500
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications +44 (0) 20 3709 5700
Mary-Jane Elliott/Matthew Neal/Chris Welsh scancell@consilium-comms.com
About Scancell
Scancell is a clinical stage biopharmaceutical company that is
leveraging its proprietary research, built up over many years of
studying the human adaptive immune system, to generate novel
medicines to treat significant unmet needs in cancer and infectious
disease. The Company is building a pipeline of innovative products
by utilising its four technology platforms: Moditope(R) and
ImmunoBody(R) for vaccines and GlyMab(R) and AvidiMab(R) for
antibodies.
Adaptive immune responses include antibodies and T cells (CD4
and CD8), both of which can recognise damaged or infected cells. In
order to destroy such cancerous or infected cells, Scancell uses
either vaccines to induce immune responses or monoclonal antibodies
(mAbs) to redirect immune cells or drugs. The Company's unique
approach is that its innovative products target modifications of
proteins and lipids. For the vaccines (Moditope(R) and
ImmunoBody(R) ) this includes citrullination and homocitrullination
of proteins, whereas its mAb portfolio targets glycans or sugars
that are added onto proteins and / or lipids (GlyMab(R) ) or
enhances the potency of antibodies and their ability to directly
kill tumour cells (AvidiMab(R) ).
For further information about Scancell, please visit:
https://www.scancell.co.uk/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFZGZRRRVGFZM
(END) Dow Jones Newswires
August 29, 2023 02:00 ET (06:00 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2023 to Apr 2024